Caley Castelein
Vorsitzender bei AADI BIOSCIENCE, INC.
Vermögen: 16 Mio $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ryan Robinson | M | - |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 1 Jahre |
| Sandeep Kulkarni | M | 43 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 3 Jahre |
| Neil Desai | M | 59 | 13 Jahre | |
| Scott Giacobello | M | 54 | 3 Jahre | |
| Joseph H. Gardner | M | 68 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 13 Jahre |
| David Lennon | M | 53 | 1 Jahre | |
| James F. Dempsey | M | 53 | 20 Jahre | |
| Paul Ziegler | M | 52 | 5 Jahre | |
| Sanket Shah | M | - | 5 Jahre | |
| Daniel Moore | M | 63 | 6 Jahre | |
| W. Middlekauff | M | 63 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 Jahre |
| Joseph W. Henein | M | - |
NewBridge Pharmaceuticals FZ LLC
 NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | 14 Jahre |
| Priya Abani | F | 49 |
AliveCor, Inc.
 AliveCor, Inc. Packaged SoftwareTechnology Services AliveCor, Inc. develops mobile heart monitoring system. It offers kardia mobile that provides people with suspected or diagnosed heart conditions, and those at risk of heart conditions. The company was founded by David E. Albert, Bruce Satchwell, and Kim Barnett and is headquartered in San Francisco, CA. | 5 Jahre |
| Anupam Dalal | M | 52 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 3 Jahre |
| Scott Drake | M | 56 | 6 Jahre | |
| Aaron Kantoff | M | 29 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 Jahre |
| Behzad Aghazadeh | M | 52 | 3 Jahre | |
| Robert McCormack | M | - | 6 Jahre | |
| Susan Jones | M | 64 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 Jahre |
| Kevin Johnson | M | 60 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 1 Jahre |
| Mitchell Brigell | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Michael Saracen | M | - | 12 Jahre | |
| Vanessa Edmunds | F | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | 11 Jahre |
| Rosie Khodeir | F | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | 11 Jahre |
| Parvinder Thiara | M | 39 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 2 Jahre |
| Yung H. Chyung | M | 48 |
Harvard College
| 6 Jahre |
| Stephen M. Rodin | M | 47 | 2 Jahre | |
| Sean Delaney | M | - | - | |
| Mohammad Hirmand | M | 54 | 1 Jahre | |
| Richard Maroun | M | 69 | 3 Jahre | |
| Karen Prange | F | 60 | 3 Jahre | |
| B. Johnson | F | 72 | 4 Jahre | |
| Ira H. Bahr | M | 61 |
AliveCor, Inc.
AliveCor, Inc. Packaged SoftwareTechnology Services AliveCor, Inc. develops mobile heart monitoring system. It offers kardia mobile that provides people with suspected or diagnosed heart conditions, and those at risk of heart conditions. The company was founded by David E. Albert, Bruce Satchwell, and Kim Barnett and is headquartered in San Francisco, CA. | 5 Jahre |
| Cassie Mahar | F | 38 | 5 Jahre | |
| Karin Hehenberger | M | 52 | 3 Jahre | |
| Clay Siegall | M | 63 |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | 1 Jahre |
| Samantha Pfeil | F | - | 3 Jahre | |
| Marcy Graham | F | 57 | 2 Jahre | |
| Andrew I. Jensen | M | - |
Kearny Venture Partners
 Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California.
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | 16 Jahre |
| Emma Reeve | F | 63 | 3 Jahre | |
| Chris Kontos | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Amanda Sequira | F | 46 | 6 Jahre | |
| Alaa Gamal | M | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | - |
| G. S. Jha | M | - | 6 Jahre | |
| Matthew Harrison | M | - | 3 Jahre | |
| Dietmar Vestweber | M | - |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Adam Podbelski | M | 45 | 6 Jahre | |
| Yasser Ferieg | M | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | - |
| Dan Low | M | - |
Viewray Technologies, Inc.
 Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | - |
| Dan Steinhoff | M | - |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | - |
| Tim Anderson | M | - |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | - |
| Berta Grigorian | F | - | 7 Jahre | |
| Raymond Steitz | M | - | 2 Jahre | |
| Wolfgang Tomé | M | - |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | - |
| Vinod Khosla | M | 69 |
AliveCor, Inc.
AliveCor, Inc. Packaged SoftwareTechnology Services AliveCor, Inc. develops mobile heart monitoring system. It offers kardia mobile that provides people with suspected or diagnosed heart conditions, and those at risk of heart conditions. The company was founded by David E. Albert, Bruce Satchwell, and Kim Barnett and is headquartered in San Francisco, CA. | 5 Jahre |
| Kevin G. Peters | M | 67 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | - |
| Andrew Kwon | M | - | 5 Jahre | |
| Mitchall G. Clark | M | 63 | 6 Jahre | |
| Kristen Hege | M | 60 |
The University of California, San Francisco
| 28 Jahre |
| Robert Michael Fuchs | M | 57 | 6 Jahre | |
| Peter Hutt | M | 89 |
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | - |
| Mark McDade | M | 69 | 1 Jahre | |
| Victor J. Dzau | M | 78 |
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | - |
| Jim M. Shapiro | M | 65 |
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | 18 Jahre |
| Dick C. Spalding | M | 73 |
Kearny Venture Partners
Kearny Venture Partners Investment ManagersFinance Kearny Venture Partners (Kearny Venture Partners) is a venture capital firm. The firm is headquartered in San Francisco, California. | - |
| Pamela Palmer | M | 61 |
The University of California, San Francisco
| 28 Jahre |
| Anas J. Meerza | M | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | - |
| Subhi Jarudi | M | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | - |
| Stephen Pakola | M | 55 |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | 9 Jahre |
| Taghreed Al-Shunnar | F | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | - |
| Qais Marafie | M | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | - |
| Loretta Itri | M | 74 | 3 Jahre | |
| Baher Massoud | M | - |
NewBridge Pharmaceuticals FZ LLC
NewBridge Pharmaceuticals FZ LLC Pharmaceuticals: MajorHealth Technology NewBridge Pharmaceuticals FZ LLC engages in the manufacture and distribution of pharmaceutical products, therapeutics and medical devices. The company was founded by G. Garrett Vygantas in 2007 and is headquartered in Dubai, United Arab Emirates. | 11 Jahre |
| Steven Annen | M | 60 | 5 Jahre | |
| Rebecca Luse | F | - |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | - |
| Martin Fuss | M | - | 7 Jahre | |
| Gerhard Hagn | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Chris A. Raanes | M | 58 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 5 Jahre |
| Dinara Akzhigitova | F | 39 | 2 Jahre | |
| Ajay Bansal | M | 62 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 3 Jahre |
| Brendan Delaney | M | 49 | 2 Jahre | |
| Aditya Puri | M | 53 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 4 Jahre |
| Josh Bilenker | M | 52 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 9 Jahre |
| David Bonita | M | 48 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 10 Jahre |
| David Chandler | M | 66 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 6 Jahre |
| Brian Roberts | M | 53 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 8 Jahre |
| Robert Mark Weisskoff | M | 61 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | - |
| R. Huennekens | M | 59 | 3 Jahre | |
| Peter B. Roemer | M | 68 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | - |
| Paul Edick | M | 67 | 3 Jahre | |
| Ross Muken | M | 44 |
Thomas Weisel Partners LLC
 Thomas Weisel Partners LLC Investment Banks/BrokersFinance Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare. | - |
| John Schmid | M | 61 | 6 Jahre | |
| Rob Steele | M | - |
Thomas Weisel Partners LLC
Thomas Weisel Partners LLC Investment Banks/BrokersFinance Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare. | 5 Jahre |
| Michael Brandt | M | 60 |
Viewray Technologies, Inc.
Viewray Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Viewray Technologies, Inc. develops radiation therapy technology for the treatment of cancer. It operates through the MRIdian system software. The company was founded by James F. Dempsey and Russell S. Donda in March 2004 and is headquartered in Oakwood Village, OH. | 4 Jahre |
| Michaella Gallina | F | - | - | |
| Mark Gold | M | 75 | - | |
| Susan Schnabel | F | 63 | 1 Jahre | |
| Henry McKinnell | M | 81 | 3 Jahre | |
| R. Knaley | M | 54 | 2 Jahre | |
| Lisa Westley | F | - |
Thomas Weisel Partners LLC
Thomas Weisel Partners LLC Investment Banks/BrokersFinance Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare. | 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 88 | 88,00% |
| Vereinigte Arabische Emirate | 11 | 11,00% |
| Kanada | 0 | -.--% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Caley Castelein
- Persönliches Netzwerk
